---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-264196"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:30:57.725570+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences faces Medicare coverage threat for OMNI system; 63% of Surgical Glaucoma revenue at risk

## Summary
- WPS LCD classifies OMNI procedure as investigational, effective Dec 24, 2023; WPS states ~8% of 2022 Surgical Glaucoma revenue.
- Four other MACs proposed similar LCDs; combined five MACs ~63% of 2022 Surgical Glaucoma revenue.
- Company evaluating FY 2023 guidance due to uncertain coverage; update on Nov 7 earnings call.
- Company disputes LCD, submitted 36-month GEMINI study for publication; will pursue all remediation.

## SEC filing metadata
- accession: 0001193125-23-264196
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000119312523264196/0001193125-23-264196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000119312523264196/d545751d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-264196
- JSON: https://secwatch.observer/filing/0001193125-23-264196.json
- Plain text: https://secwatch.observer/filing/0001193125-23-264196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.